🔍 Key Finding

AI shows significant promise for advancing psychodermatology by improving diagnostic precision, treatment effectiveness, and personalized care, though challenges remain regarding implementation and validation.

🔬 Methodology Overview

• Design: Literature review following PRISMA guidelines

• Data Sources: PubMed and Google Scholar (2004-2024)

• Selection Criteria: Studies applying AI to psychodermatological conditions, human subjects, English language

• Assessment: Critical Appraisal Skills Program (CASP) tool for risk of bias

• Included Studies: 3 studies (one qualitative study, one RCT, one systematic review)

📊 Evidence

• Machine learning predicted BDD remission with 78% accuracy in a 94-patient RCT comparing ICBT to online supportive therapy

• SVM models achieved AUCs of 0.77 for treatment response, 0.75 for partial remission, and 0.79 for full remission in 97 BDD patients receiving escitalopram

• Key predictors of better outcomes included lower DLQI scores and reduced hopelessness

• Machine learning identified biomarkers linking anxiety disorders with increased autophagy, immune dysregulation, and inflammation

💡 Clinical Impact

AI enables more precise and individualized care by improving screening, diagnosis, and treatment planning for psychodermatological conditions, potentially addressing the knowledge gap among dermatologists (only 13.75% thoroughly understand psychocutaneous disorders).

🤔 Limitations

• Scarcity of studies specifically exploring AI in psychodermatology

• Heterogeneity among the limited studies available

• Potential biases in datasets limit generalizability

• Current AI datasets often lack diversity, leading to biased outcomes